The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy.
 
David Liu
No Relationships to Disclose
 
Philip Abbosh
Honoraria - Ashion Advanced Individual Medicine
 
Diana Miao
No Relationships to Disclose
 
Mariel Elena Boyd
No Relationships to Disclose
 
Jean H. Hoffman-Censits
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Gopa Iyer
No Relationships to Disclose
 
Sara M. Tolaney
No Relationships to Disclose
 
Kent William Mouw
No Relationships to Disclose
 
Scott L. Carter
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Acceleron Pharma (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Eliezer Mendel Van Allen
Consulting or Advisory Role - Roche; Syapse; Takeda; Third Rock Ventures
Research Funding - Bristol-Myers Squibb